Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asia Green Biotechnology's quarterly market cap
stayed the same
from Mar. 2024 (C$0.54 Mil) to Jun. 2024 (C$0.54 Mil) and
stayed the same
from Jun. 2024 (C$0.54 Mil) to Sep. 2024 (C$0.54 Mil).
Asia Green Biotechnology's annual market cap
declined
from Dec. 2021 (C$1.45 Mil) to Dec. 2022 (C$0.54 Mil) and
declined
from Dec. 2022 (C$0.54 Mil) to Dec. 2023 (C$0.36 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Asia Green Biotechnology's Enterprise Value for Today is C$0.79 Mil.
Asia Green Biotechnology (XCNQ:ASIA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Asia Green Biotechnology Market Cap Related Terms
Asia Green Biotechnology Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Asia Green Biotechnology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asia Green Biotechnology Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asia Green Biotechnology's Market Cap distribution charts can be found below:
* The bar in red indicates where Asia Green Biotechnology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Asia Green Biotechnology's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asia Green Biotechnology (XCNQ:ASIA) has a Market Cap of C$0.54 Mil as of Jul. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Asia Green Biotechnology and its competitors.
Is Asia Green Biotechnology's Market Cap too high?
Asia Green Biotechnology's current Market Cap is C$0.54 Mil.
How does Asia Green Biotechnology's Market Cap compare to ZTS?
Asia Green Biotechnology's Market Cap of C$0.54 Mil can be compared against companies in the Drug Manufacturers industry. The industry median Market Cap is 215.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 215.70, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Asia Green Biotechnology and its competitors. For the Drug Manufacturers industry, the median Market Cap is 215.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asia Green Biotechnology's current Market Cap is C$0.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asia Green Biotechnology stock overvalued right now?
Asia Green Biotechnology (XCNQ:ASIA) has a current Market Cap of C$0.54 Mil. The current Market Cap is C$0.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Asia Green Biotechnology (XCNQ:ASIA), the current Market Cap is C$0.54 Mil as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asia Green Biotechnology Corp is an early stage international agri-technology company focused on the development, evaluation, testing, application and, ultimately, supply to the market of proprietary organic hybridization technology and certain products derived from that technology. The core approach of the business is centred on the planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities. The company is developing varieties of hemp with superior growth and production characteristics in the various environments found in the licensed territories.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:ASIA has been successfully added to your 
